Fate Therapeutics, Inc. (FATE) Stock Analysis
A live, multi-source view of Fate Therapeutics, Inc. (FATE): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Sector: Healthcare · Industry: Biotechnology · United States · 161 employees · fatetherapeutics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Fate Therapeutics, Inc. (FATE) had a market capitalization of $297.2M (forward -2.6) and a beta of 2.55; the shares traded in a 52-week range of $0.93 – $3.23 (139.6% over the year).
- Market cap
- $297.2M
- Enterprise value
- $219.1M
- Forward P/E
- -2.6
- Price / book
- 1.89
- EPS (trailing)
- $-1.05
- EPS (forward)
- $-0.97
- Payout ratio
- 0.0%
- 52-week range
- $0.93 – $3.23
- 52-week change
- 139.6%
- Beta
- 2.55
- Average volume
- 2.9M
- Shares outstanding
- 119.8M
- Short % of float
- 8.02%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Fate Therapeutics, Inc. (FATE) last closed at $2.44 (the last completed close before that scan).
Technicals at the scan: RSI 46 (neutral territory), price -2.4% versus its 20-day average, 20-day versus 50-day average spread -5.3%, MACD histogram -0.00.
Sentiment inputs: 33% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; Reddit mentions -50% over 24 hours; analyst consensus score 64/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of FATE; corporate insiders filed 0 buys and 2 sells (2 distinct filers, latest disclosure 2026-08-05). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Bahram Valamehr (0B/1S), Cindy Tahl (0B/1S). Who is trading what
RapidTradeView pick record
FATE has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Fate Therapeutics, Inc. (FATE) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell FATE.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.